Body fat distribution and insulin resistance: Beyond obesity in nonalcoholic fatty liver disease among overweight men

Journal of the American College of Nutrition

Volumn 26, Issue 4, 2007, Pages 321-326

  Park, Seung Ha ^a   Kim, Byung Ik ^a   Kim, Sang Hoon ^a   Kim, Hong Joo ^a   Park, Dong Il ^a   Cho, Yong Kyun ^a   Sung, In Kyung ^b   Sohn, Chong Il ^a   Kim, Hyang ^a   Keum, Dong Keuk ^a   Kim, Heung Dae ^a   Park, Jung Ho ^a   Kang, Jin Ho ^a   Jeon, Woo Kyu ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

Central adiposity; Insulin resistance; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; FAT; IRON; TRIACYLGLYCEROL;

ABDOMINAL FAT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; WAIST CIRCUMFERENCE;

ABDOMINAL FAT; ADULT; BODY COMPOSITION; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ELECTRIC IMPEDANCE; FATTY LIVER; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; OVERWEIGHT; RISK FACTORS; WAIST-HIP RATIO;

EID: 35348815566     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2007.10719618     Document Type: Article

References (36)

1. Mulhall BP, Ong JP, Younossi ZM: Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 17:1136–1143, 2002.
2. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 27:142–149, 1988.
3. Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, Ohba K, Isomoto H, Mizuta Y, Hayashida K, Murase K, Kadota T, Murata I, Kohno S: Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17:1098–1105, 2002.
4. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112–117, 2000.
5. Hsiao TJ, Chen JC, Wang JD: Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 28: 167–172, 2004.
6. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M: Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 39:754–763, 2004.
7. Kral JG, Schaffner F, Pierson RN Jr, Wang J: Body fat topography as an independent predictor of fatty liver. Metabolism 42:548–551, 1993.
8. Kahn BB, Flier JS: Obesity and insulin resistance. J Clin Invest 106:473–481, 2000.
9. Angulo P, Lindor KD: Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17:S186–S190, 2002.
10. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G: Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100:1166–1173, 1997.
11. Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM: Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40:937–943, 2002.
12. Younossi ZM: Nonalcoholic fatty liver disease. Curr Gastroenterol Rep 1:57–62, 1999.
13. Coates RA, Halliday ML, Rankin JG, Feinman SV, Fisher MM: Risk of fatty infiltration or cirrhosis of the liver in relation to ethanol consumption: a case-control study. Clin Invest Med 9:26–32, 1986.
14. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M: Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku J Exp Med 139:43–50, 1983.
15. Mathews DR, Hoskers JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment of insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419, 1985.
16. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO consultation, Geneva, 3–5 June 1997. Geneva: WHO, 1998. (WHO/NUT/98.1.)
17. Whang IT, Ryu KH, Kim KH, Hong YM, Kim GH, Lee K: Percent of body fat by bioelectrical impedance analysis in healthy children. Korean Pediatr Soc 42:1207–1214, 1999.
18. Malavolti M, Mussi C, Poli M, Fantuzzi AL, Salvioli G, Battistini N, Bedogni G.: Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21–82 years. Ann Hum Biol 30:380–391, 2003.
19. Diehl AM: Obesity and alcohol liver disease. Alcohol 34:81–87, 2004.
20. Ramesh S, Sanyal AJ: Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 24:399–413, 2004.
21. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745–750, 2002.
22. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450–455, 1999.
23. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, Sung IK, Park CY, Sohn CI, Jeon WK, Kim H, Rhee EJ, Lee WY, Kim SW: Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 19:694–698, 2004.
24. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40:46–54, 2004.
25. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin resistance: Insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology 35:373–379, 2002.
26. Bjorntorp P: “Portal” adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10:493–496, 1990.
27. Day CP, James OF: Steatohepatitis: a tale of two “hits”? Gastroenterology 114:842–845, 1998.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497, 2001.
29. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, Klein RL, Garvey WT: Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978–983, 2004.
30. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES: Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53:1195–1200, 2004.
31. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923, 2003.
32. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960–967, 2003.
33. Ruhl CE, Everhart JE: Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124:71–79, 2003.
34. Hsieh SD, Yoshinaga H: Is there any difference in coronary heart disease risk factors and prevalence of fatty liver in subjects with normal body mass index having different physiques? Tohoku J Exp Med 177:223–231, 1995.
35. Ruhl CE, Everhart JE: Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 124:1821–1829, 2003.
36. Lonardo A, Loria P, Leonardl F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, Bagni A, Bertolotti M, Ganazzi D, Carulli N; POLI.ST.E.N.A. Study Group. Policentrica Steatosi Epatica Non Alcolica: Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of nonalcoholic fatty liver disease. A case-control study. Dig Liver Dis 34:204–211, 2002.